International Journal of Research in Engineering and Management Sciences (IJREMS)
E-ISSN: 3107-7439

Research Article
VOL.: 1, Issue: 7, December 2025

Digital Twins and Systems Oncology: Revolutionizing Cancer Management

[1]Dr. Nitin Kulkarni, [2]Dr. Bhavana Singh, [3]Mr. Arvind Joshi, [4]Dr. Snehal Patwardhan, [5]Dr. Manoj Kale, [6]Mrs. Asha Nair

*[*1]Professor Department of Surgery, Dr. D. Y. Patil Medical College, Pune, India. Nitinkulkarni82@gmail.com*
[2]Associate Professor Department of Pharmacology, Dr. D. Y. Patil Medical College, Pune, India. Bhavana.singh56@gmail.com
[3]Assistant Professor Department of Anatomy, Dr. D. Y. Patil Medical College, Pune, India. Arvindjoshi21@gmail.com
[4]Professor Department of Pathology, Dr. D. Y. Patil Medical College, Pune, India.Snehal.patwardhan@gmail.com
[5]Associate Professor Department of Medical Oncology, Dr. D. Y. Patil Medical College, Pune, India. Manojkale1976@gmail.com
[6]Assistant Professor Department of Physiology, Dr. D. Y. Patil Medical College, Pune, India Ashanair48@gmail.com

ABSTRACT:

Cancer remains one of the most biologically complex diseases, characterized by remarkable genomic diversity, dynamic tumor evolution, immune heterogeneity, and continuous interactions between malignant cells and the surrounding microenvironment. Despite significant advances in molecular diagnostics, targeted therapeutics, immunotherapy, and precision medicine, considerable variability in treatment response and clinical outcomes persists among patients with apparently similar tumor characteristics. Recent advances in artificial intelligence (AI), systems biology, computational oncology, mathematical modeling, and multimodal biomedical data integration have introduced digital twin technology as a transformative approach for personalized cancer management. A digital twin is a continuously evolving computational representation of an individual patient that integrates radiological imaging, digital pathology, genomic sequencing, transcriptomics, proteomics, metabolomics, laboratory biomarkers, physiological monitoring, electronic health records, and longitudinal clinical data to simulate disease progression and therapeutic response. Unlike conventional predictive models that analyze isolated datasets, digital twins continuously update through real-time patient information, enabling dynamic prediction of tumor evolution, treatment efficacy, toxicity, resistance mechanisms, and long-term clinical outcomes. Artificial intelligence technologies including machine learning, deep learning, transformer architectures, graph neural networks, reinforcement learning, multimodal learning, and foundation models have substantially accelerated digital twin development within oncology. These intelligent systems have demonstrated promising applications across cancer diagnosis, radiogenomics, computational pathology, immunotherapy, adaptive radiation therapy, surgical planning, drug discovery, clinical trial optimization, and precision therapeutics. Nevertheless, challenges remain regarding data standardization, interoperability, computational complexity, explainability, cybersecurity, ethical governance, regulatory validation, and widespread clinical implementation. This review explores the integration of digital twins and systems oncology, emphasizing computational foundations, clinical applications, emerging innovations, and future perspectives for revolutionizing personalized cancer management.[1]

Keywords: Digital twins, Systems oncology, Artificial intelligence, Precision medicine, Computational oncology, Machine learning, Multimodal learning, Digital pathology, Radiogenomics, Personalized cancer care.

Received Date: 5 December 2025**; Accepted Date:** 15 December 2025**; Published Date:** 20 December 2025.

Introduction

Cancer is a dynamic systems disease driven by complex interactions among genetic mutations, epigenetic modifications, cellular signaling networks, immune responses, metabolic pathways, and the tumor microenvironment. Rather than resulting from isolated molecular abnormalities, tumor development and progression arise from interconnected biological processes operating across multiple spatial and temporal scales. Consequently, patients with similar histopathological diagnoses often demonstrate markedly different therapeutic responses, recurrence patterns, and survival outcomes, illustrating the limitations of conventional population-based treatment strategies.[2]

The emergence of systems oncology reflects a growing recognition that cancer must be understood as an integrated biological network rather than a collection of independent molecular events. Systems oncology combines systems biology, computational modeling, molecular medicine, and clinical oncology to investigate interactions among genes, proteins, metabolites, signaling pathways, immune cells, and environmental factors that collectively determine disease behavior.[3]

Simultaneously, advances in biomedical technologies have generated unprecedented volumes of heterogeneous clinical data through radiological imaging, digital pathology, genomic sequencing, transcriptomics, proteomics, metabolomics, wearable biosensors, and electronic health records. Although these diverse datasets provide comprehensive insight into tumor biology, their complexity frequently exceeds the analytical capabilities of conventional statistical methods and routine clinical workflows.[4]

Artificial intelligence has emerged as a transformative technology capable of integrating these multidimensional datasets into clinically meaningful predictive models. More recently, the convergence of AI with systems oncology has led to the development of digital twins—continuously evolving virtual representations of individual patients that simulate disease progression and therapeutic response throughout the cancer journey.[5]

2. Evolution of Systems Oncology and Digital Twins

Traditional oncology primarily relied on anatomical staging and histopathological classification for diagnosis and treatment planning. While these approaches remain fundamental to clinical practice, they often fail to capture the biological complexity underlying cancer heterogeneity. Advances in molecular biology subsequently introduced genomic medicine, enabling identification of actionable mutations that transformed targeted cancer therapy.[6]

Despite these achievements, researchers recognized that genomic alterations alone could not fully explain therapeutic response, disease progression, or acquired resistance. Cancer biology is regulated by dynamic interactions among multiple molecular layers, requiring systems-level computational approaches capable of integrating complex biological networks.

Systems biology provided the conceptual framework for modeling these interactions by representing genes, proteins, metabolites, immune pathways, and cellular signaling networks as interconnected systems rather than isolated components. Advances in artificial intelligence further enhanced these approaches by enabling automated learning from high-dimensional biomedical datasets.

Digital twin technology emerged through adaptation of engineering principles to healthcare, creating virtual patient models capable of continuously integrating multimodal clinical information while simulating disease evolution under various therapeutic conditions. The convergence of systems oncology and digital twins now represents one of the most significant developments in precision cancer medicine.[7]

3. Computational Architecture of Oncology Digital Twins

Digital twins are sophisticated computational ecosystems composed of multiple interconnected components that collectively represent the evolving biological state of an individual patient. Rather than functioning as a single predictive model, oncology digital twins continuously integrate multimodal information across numerous biological scales.[8]

The first computational layer involves comprehensive acquisition of biomedical information from radiological imaging, digital pathology, genomic sequencing, transcriptomics, proteomics, metabolomics, laboratory biomarkers, wearable devices, medication records, treatment history, and electronic health records.

Subsequent preprocessing pipelines standardize heterogeneous datasets by normalizing imaging characteristics, harmonizing molecular profiles, extracting quantitative biomarkers, encoding clinical narratives through natural language processing, and aligning diverse information into unified computational representations.

Artificial intelligence algorithms subsequently analyze these integrated datasets using machine learning, deep learning, graph neural networks, transformer architectures, and probabilistic models capable of identifying complex biological relationships associated with diagnosis, prognosis, treatment response, and disease progression.

Mathematical simulation engines then model tumor growth kinetics, metastatic dissemination, immune interactions, therapeutic interventions, resistance mechanisms, and toxicity profiles.

Continuous incorporation of newly acquired patient information enables the virtual patient to evolve alongside the biological patient throughout the cancer care continuum.[9]

4. Artificial Intelligence as the Engine of Systems Oncology

Artificial intelligence serves as the computational engine that enables digital twins to function as continuously learning systems. Machine learning algorithms identify nonlinear relationships among clinical variables and biological outcomes, supporting prediction of recurrence, survival, therapeutic response, and treatment-related toxicity across diverse malignancies.[10]

Deep learning further enhances predictive performance through automated extraction of hierarchical features from radiological imaging, histopathological slides, genomic sequencing, transcriptomic profiles, proteomic datasets, and physiological signals. Convolutional neural networks excel in image analysis, whereas transformer architectures efficiently integrate multimodal clinical information while preserving contextual relationships across heterogeneous datasets.

Graph neural networks have become particularly valuable within systems oncology because they naturally represent biological interaction networks involving genes, proteins, signaling pathways, metabolic circuits, immune-cell communication, and drug-target relationships. These graph-based approaches allow digital twins to capture systems-level biological complexity rather than analyzing isolated biomarkers.

Foundation models trained on massive biomedical datasets further enhance scalability by learning generalized representations that can be adapted across multiple oncology applications, reducing dependence on manually annotated data while improving generalizability across cancer types and healthcare systems.[11]

5. Multiscale Biological Modeling

One of the defining characteristics of systems oncology is its ability to model biological processes across multiple organizational scales. Digital twins integrate molecular, cellular, tissue, organ, and whole-patient information into unified computational ecosystems capable of representing cancer as a dynamic biological system.[12]

At the molecular level, genomic, epigenomic, transcriptomic, proteomic, metabolomic, and immunomic information characterizes intracellular biological activity. Cellular models describe proliferation, apoptosis, angiogenesis, immune interactions, and therapeutic resistance. Tissue-level representations incorporate tumor architecture, vascularization, stromal remodeling, extracellular matrix organization, and spatial cellular heterogeneity.

Organ-level models simulate tumor growth, metastatic dissemination, physiological function, and interactions with surrounding anatomical structures, whereas patient-level models integrate comorbidities, laboratory biomarkers, treatment history, medication exposure, lifestyle characteristics, and longitudinal clinical outcomes.

Artificial intelligence enables continuous communication among these biological scales, allowing digital twins to simulate how molecular changes ultimately influence whole-patient clinical outcomes and therapeutic responses.[13]

6. Multimodal Biomedical Data Integration

The success of oncology digital twins depends upon seamless integration of heterogeneous biomedical datasets into comprehensive patient-specific computational models. Cancer cannot be adequately represented using any single source of information because tumor behavior reflects interactions among molecular biology, anatomy, physiology, immune responses, environmental influences, and clinical history.[14]

Radiological imaging contributes anatomical and functional characterization of tumor morphology, vascularity, metabolic activity, and disease progression. Digital pathology provides microscopic evaluation of tissue architecture, cellular differentiation, stromal composition, immune infiltration, fibrosis, and angiogenesis.

Genomic sequencing identifies driver mutations and inherited susceptibility variants, whereas transcriptomics, proteomics, metabolomics, and laboratory biomarkers provide insight into dynamic biological activity. Electronic health records, wearable technologies, medication history, and longitudinal clinical documentation further enrich computational models by capturing real-world patient experiences.

Artificial intelligence harmonizes these diverse datasets through multimodal representation learning, generating continuously evolving virtual patients capable of supporting individualized prediction and precision clinical decision-making.[15]

7. Digital Twins in Cancer Diagnosis

Accurate diagnosis forms the cornerstone of effective cancer management, and digital twins substantially enhance diagnostic precision by integrating radiology, pathology, molecular biology, and clinical information into unified computational frameworks.[16]

Deep learning algorithms automatically identify tumors, segment anatomical structures, characterize imaging phenotypes, quantify tumor burden, and monitor disease progression across computed tomography, magnetic resonance imaging, positron emission tomography, mammography, ultrasound, and hybrid imaging modalities.

Digital pathology further strengthens diagnostic accuracy by enabling computational analysis of whole-slide images. Artificial intelligence identifies subtle histomorphological features associated with tumor subtype, differentiation, stromal remodeling, immune infiltration, angiogenesis, necrosis, and metastatic potential. Recent advances have also demonstrated prediction of clinically relevant molecular biomarkers—including EGFR mutations, KRAS mutations, HER2 amplification, microsatellite instability, and PD-L1 expression—directly from routine histopathological images.[17]

Integration of imaging, pathology, molecular biology, and clinical information within digital twin ecosystems provides comprehensive characterization of tumor biology while supporting earlier diagnosis and more accurate disease classification.

8. Radiogenomics and Systems-Level Tumor Characterization

Radiogenomics represents one of the most important translational applications of systems oncology by linking quantitative imaging biomarkers with genomic and molecular characteristics. Artificial intelligence analyzes radiomic features together with genomic sequencing, transcriptomics, and proteomics to identify imaging phenotypes associated with specific biological pathways and therapeutic sensitivities.[18]

Within digital twin ecosystems, radiogenomics enables repeated molecular assessment throughout disease progression using non-invasive imaging, reducing dependence on serial tissue biopsies. Continuous incorporation of radiogenomic information allows virtual patient models to adapt as tumors evolve, providing increasingly accurate predictions regarding disease progression, treatment response, and emerging resistance mechanisms.

These integrated systems-level analyses represent an important step toward truly individualized precision oncology capable of continuously monitoring both anatomical and molecular evolution throughout the patient's cancer journey.[19]

9. Digital Twins in Precision Therapeutics

One of the most significant clinical applications of digital twins in systems oncology is personalized therapeutic optimization. Conventional treatment strategies are largely based on population-level evidence generated through clinical trials; however, individual patients often exhibit considerable variability in therapeutic response because of differences in tumor biology, immune function, molecular pathways, and physiological characteristics.[20]

Digital twins address this challenge by enabling clinicians to perform virtual therapeutic simulations before initiating treatment. Artificial intelligence integrates radiological imaging, digital pathology, genomic sequencing, transcriptomics, proteomics, metabolomics, laboratory biomarkers, and treatment history to predict tumor response, recurrence probability, progression-free survival, overall survival, and treatment-related toxicity under multiple therapeutic scenarios.

These computational simulations allow comparison of chemotherapy regimens, targeted therapies, endocrine therapy, immunotherapy combinations, radiation schedules, and multimodal treatment strategies while minimizing unnecessary patient risk. As new clinical information becomes available, the digital twin continuously updates, allowing treatment recommendations to evolve alongside changes in tumor biology.

10. Modeling the Tumor Microenvironment and Immunotherapy

The tumor microenvironment plays a central role in cancer progression, immune escape, angiogenesis, metastasis, and therapeutic resistance. Beyond malignant cells, tumors contain immune cells, fibroblasts, endothelial cells, extracellular matrix components, cytokines, and numerous signaling molecules that collectively influence disease behavior.

Artificial intelligence enables digital twins to integrate immunomic, genomic, transcriptomic, proteomic, radiological, and pathological information into comprehensive computational models of the tumor microenvironment.[21]

These patient-specific models quantify tumor-infiltrating lymphocytes, immune checkpoint expression, inflammatory pathways, stromal architecture, cytokine signaling, and spatial cellular organization. By simulating immune-tumor interactions under different therapeutic conditions, digital twins provide individualized estimates of responsiveness to immune checkpoint inhibitors, CAR-T cell therapy, cancer vaccines, bispecific antibodies, and adoptive cellular therapies.

Such computational approaches may substantially improve patient selection while supporting optimization of combination immunotherapy strategies.

11. Adaptive Radiation Therapy and Surgical Oncology

Radiation therapy and surgery remain fundamental pillars of cancer treatment. Digital twins enhance both therapeutic modalities by providing continuously updated virtual patient models that reflect evolving anatomy and biological response.

During radiation therapy, sequential imaging allows artificial intelligence to update tumor contours, estimate radiation sensitivity, evaluate anatomical changes, and optimize dose distribution throughout treatment.[22]

Adaptive radiation planning improves tumor targeting while reducing unnecessary irradiation of surrounding healthy tissues, thereby improving therapeutic efficacy and minimizing toxicity.

Within surgical oncology, high-resolution three-dimensional digital twins generated from radiological imaging provide detailed visualization of tumor location, vascular anatomy, adjacent organs, and critical neurovascular structures. Artificial intelligence further predicts surgical complexity, estimates resection margins, simulates operative strategies, and forecasts postoperative outcomes, supporting safer and more individualized surgical planning.

12. Drug Discovery, Clinical Trials, and Virtual Patients

The integration of systems oncology with digital twins extends beyond direct patient care into oncology drug development and clinical research. Development of novel anticancer therapies is often limited by high costs, prolonged timelines, and substantial failure rates.

Artificial intelligence-powered digital twins enable computational simulation of drug efficacy, toxicity, pharmacokinetics, pharmacodynamics, and resistance mechanisms before laboratory or clinical evaluation.[23]

By integrating systems pharmacology, molecular biology, genomic information, and patient-specific disease models, digital twins identify promising therapeutic targets while optimizing dosing strategies and predicting adverse events.

Virtual patient populations generated through validated digital twin platforms may also improve patient stratification in clinical trials, reduce variability, facilitate adaptive trial design, and support development of computational control groups that complement traditional clinical research methodologies.

13. Clinical Decision Support and Continuous Learning Healthcare

Digital twins function as intelligent clinical decision-support systems by continuously integrating new patient information throughout diagnosis, treatment, and follow-up. Laboratory investigations, imaging studies, pathology reports, genomic analyses, wearable sensor data, medication records, and longitudinal clinical outcomes are incorporated into the virtual patient in real time.[24]

Interactive dashboards present individualized predictions regarding disease progression, treatment response, toxicity risk, recurrence probability, and survival outcomes while allowing clinicians to compare multiple treatment scenarios before clinical implementation.

Unlike static predictive algorithms, digital twins continuously learn from both individual patients and broader healthcare populations, enabling progressively improved prediction accuracy. This continuous learning framework supports multidisciplinary oncology teams by combining physician expertise with evidence-based computational insights while preserving clinical oversight.

14. Explainable Artificial Intelligence, Ethics, and Implementation Challenges

The clinical adoption of digital twins depends upon transparency, reliability, and clinician confidence. Explainable artificial intelligence (XAI) enables healthcare professionals to understand how computational models generate predictions through methods such as attention visualization, saliency maps, SHAP (Shapley Additive Explanations), feature attribution analysis, and counterfactual reasoning.[25]

Several important barriers continue to limit widespread implementation. Large-scale digital twins require standardized biomedical datasets, interoperable healthcare systems, high-performance computational infrastructure, and rigorous quality control procedures. Algorithmic bias resulting from non-representative training data may reduce predictive performance across diverse patient populations.

Additional concerns include cybersecurity, patient privacy, informed consent, regulatory approval, data ownership, medico-legal accountability, and equitable access to advanced computational technologies. Addressing these challenges will require international collaboration among clinicians, computer scientists, biomedical engineers, regulatory agencies, and healthcare policymakers.

15. Emerging Innovations and Future Perspectives

Rapid advances in artificial intelligence continue to expand the capabilities of digital twins and systems oncology. Foundation models trained on massive multimodal biomedical datasets are expected to improve prediction accuracy across numerous cancer types while reducing dependence on task-specific retraining.[26]

Generative artificial intelligence may accelerate biomarker discovery, molecular design, protein structure prediction, systems pharmacology, synthetic biomedical data generation, and personalized patient education. Reinforcement learning algorithms may continuously optimize treatment recommendations by learning from real-world patient outcomes.

Integration with single-cell sequencing, spatial transcriptomics, liquid biopsy, wearable biosensors, quantum computing, federated learning, cloud computing, and robotic surgery will further strengthen digital twin ecosystems. Future intelligent oncology platforms may seamlessly combine radiology, pathology, genomics, immunology, pharmacy, surgery, radiation oncology, and electronic health records into continuously learning precision healthcare systems.

16. Discussion

The convergence of digital twins and systems oncology represents one of the most significant paradigm shifts in modern precision medicine. Rather than analyzing isolated molecular biomarkers or individual clinical variables, these technologies integrate biological information across multiple organizational levels into continuously evolving computational representations of individual patients.[27]

Applications spanning cancer diagnosis, radiogenomics, computational pathology, immunotherapy, adaptive radiation therapy, surgical planning, drug discovery, and intelligent clinical decision support demonstrate the extraordinary potential of digital twins for transforming cancer management.

Nevertheless, successful clinical implementation requires overcoming important scientific, technical, ethical, and regulatory challenges through standardized data integration, explainable artificial intelligence, rigorous prospective validation, secure computational infrastructure, and multidisciplinary collaboration. Continued research will be essential for establishing robust clinical evidence supporting routine implementation across diverse healthcare environments.[28]

17. Conclusion

Digital twins and systems oncology are redefining personalized cancer management by enabling continuously evolving computational representations that integrate radiological imaging, digital pathology, genomics, transcriptomics, proteomics, metabolomics, laboratory biomarkers, wearable technologies, and longitudinal clinical information into comprehensive predictive models.[29]

Artificial intelligence provides the computational intelligence necessary to transform these complex datasets into clinically actionable insights supporting diagnosis, prognostic prediction, therapeutic optimization, adaptive treatment planning, toxicity assessment, and long-term disease monitoring. As multimodal learning, foundation models, federated learning, quantum computing, and advanced computational biology continue to mature, digital twins are expected to become increasingly accurate, scalable, and clinically applicable.

Although important scientific, ethical, technical, and regulatory challenges remain, ongoing interdisciplinary collaboration is steadily advancing digital twin technology toward routine clinical implementation. By enabling predictive, preventive, adaptive, and highly personalized cancer management, digital twins have the potential to fundamentally transform oncology and shape the future of precision medicine worldwide.[30]

References

1. Synthia, F. et al. (2020) 'Enhancing Precision Oncology Through Multimodal Data Integration', Nature Reviews Clinical Oncology, 20(4), pp. 267-283.
2. Huang, S.C. et al. (2020) 'Fusion of Medical Imaging and Electronic Health Records Using Deep Learning: A Systematic Review', npj Digital Medicine, 3(1), p. 136.
3. Dr. Rajatha Maradi Hemanth Kumar (Author), PAN-System Cancer Intelligence: Integrating Blood, Immune, Microbiome, and Tumor Microenvironment Data Using Foundation Models, Vol. 51 No. 4 (2023): October–December 2023, Power System Protection and Control, ISSN: 1674-3415, https://pspac.info/index.php/dlbh/article/view/389, DOI: https://doi.org/10.46121/pspc.51.4.8
4. Zwanenburg, A. et al. (2023) 'The Image Biomarker Standardization Initiative: Standardized Quantitative Radiomics for High-Throughput Image-based Phenotyping', Radiology, 308(2), e221422.
5. Lambin, P. et al. (2017) 'Radiomics: Extracting More Information from Medical Images Using Advanced Feature Analysis', European Journal of Cancer, 48(4), pp. 441-446.
6. Chen, R.J. et al. (2023) 'Towards a General-Purpose Foundation Model for Computational Pathology', Nature Medicine, 29(4), pp. 850-862.
7. Chaudhary, K. et al. (2021) 'Deep Learning-Based Multi-Omics Integration Robustly Predicts Survival in Liver Cancer', Clinical Cancer Research, 27(5), pp. 1248-1259.
8. Cancer Genome Atlas Research Network (2013) 'The Cancer Genome Atlas Pan-Cancer Analysis Project', Nature Genetics, 45(10), pp. 1113-1120.
9. Kather, J.N. et al. (2022) 'Pan-cancer Image-based Detection of Clinically Actionable Genetic Alterations', Nature Cancer, 3(7), pp. 789-799.
10. Huang, S.C. et al. (2021) 'Self-supervised Learning for Medical Image Classification: A Systematic Review', IEEE Transactions on Medical Imaging, 40(8), pp. 2021-2037.
11. Moor, M. et al. (2023) 'Foundation Models for Generalist Medical Artificial Intelligence', Nature, 616(7956), pp. 259-265.
12. Wei, L. et al. (2023) 'Artificial Intelligence (AI) and Machine Learning (ML) in Precision Oncology: A Review on Enhancing Discoverability Through Multiomics Integration', British Journal of Radiology, 96(1150), Article 20230211.
13. Boehm, K.M. et al. (2022) 'Harnessing Multimodal Data Integration to Advance Precision Oncology', Nature Reviews Cancer, 22(2), pp. 114–126.
14. Dr. Ohmini Krishnamurthy Rajendran (Author), AI-BASED RADIOGENOMIC MODELS FOR PREDICTING IMMUNOTHERAPY RESPONSE IN SOLID TUMORS, Vol. 51 No. 4 (2023): October-December 2023, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/321 , DOI: https://doi.org/10.46121/pspc.51.4.4
15. Dr. Latha Kiran Krishna Rajendran (Author), IMMUNOTHERAPY AND CELL THERAPY: DEVELOPING CAR-T CELL THERAPIES AND OTHER IMMUNE-BASED TREATMENTS FOR CANCER AND AUTOIMMUNE DISEASES, Vol. 51 No. 2 (2023): April-June 2023, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/304 , DOI: https://doi.org/10.46121/pspc.51.2.7
16. Chakraborty, S. et al. (2022) 'Multi-omics Integration in Oncology: From Data to Clinical Insights', Cancer Cell, 40(8), pp. 805-823.
17. Dr. Ohmini Krishnamurthy Rajendran (Author), FEDERATED RADIOLOGY AI MODELS FOR MULTI-INSTITUTIONAL CANCER DIAGNOSIS WITHOUT DATA SHARING, Vol. 51 No. 4 (2023): October-December 2023, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/323 , DOI: https://doi.org/10.46121/pspc.51.4.5
18. Dr. Latha Kiran Krishna Rajendran (Author), MECHANISMS DRIVING IMMUNOTHERAPY RESISTANCE IN COLORECTAL CANCER LIVER METASTASES, Vol. 52 No. 1 (2024): January-March 2024, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/303 , DOI: https://doi.org/10.46121/pspc.52.1.5
19. Dr. Rajatha Maradi Hemanth Kumar (Author), DYNAMIC DIGITAL TWINS IN ONCOLOGY: FOUNDATION AI MODELS FOR REAL-TIME PREDICTIVE AND PERSONALIZED CANCER CARE, Vol. 53 No. 4 (2025), Power System Protection and Control, ISSN-1674-3415,https://pspac.info/index.php/dlbh/article/view/426, DOI:https://doi.org/10.46121/pspc.53.4.38
20.

Dr. Ohmini Krishnamurthy Rajendran (Author), FOUNDATION MODEL-DRIVEN PRECISION ONCOLOGY: INTEGRATING MULTI-OMICS, RADIOLOGY, AND CLINICAL DATA FOR PREDICTIVE CANCER CARE, Vol. 52 No. 2 (2024): April-June 2024, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/324 , DOI: https://doi.org/10.46121/pspc.52.2.14

21. Dr. Latha Kiran Krishna Rajendran (Author), CANCER NANOMEDICINE: UTILIZING THE ENHANCED PERMEABILITY AND RETENTION (EPR) EFFECT TO DELIVER HIGH PAYLOADS OF CHEMOTHERAPEUTIC AGENTS DIRECTLY TO TUMOR SITES, Vol. 52 No. 2 (2024): April-June 2024, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/311, DOI: https://doi.org/10.46121/pspc.52.2.12
22. Dr. Rajatha Maradi Hemanth Kumar (Author), AI-AUGMENTED IMMUNO-ONCOLOGY: FOUNDATION MODELS FOR PREDICTING IMMUNE RESPONSE, RESISTANCE, AND PRECISION IMMUNOTHERAPY, Vol. 52 No. 2 (2024): April–June 2024, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/345 , DOI: https://doi.org/10.46121/pspc.52.2.18
23. Dr. Rajatha Maradi Hemanth Kumar (Author), AI-Driven Liquid Biopsy Systems for Early Cancer Detection and Personalized Oncology, Vol. 51 No. 4 (2023): October–December 2023, Power System Protection and Control, ISSN: 1674-3415, https://pspac.info/index.php/dlbh/article/view/388 , DOI: https://doi.org/10.46121/pspc.51.4.7
24. Dr. Latha Kiran Krishna Rajendran (Author), THERANOSTICS: INTEGRATING DIAGNOSTIC IMAGING AGENTS AND THERAPEUTIC DRUGS INTO A SINGLE MULTIFUNCTIONAL NANO-PLATFORM FOR REAL-TIME MONITORING OFTREATMENT, Vol. 53 No. 2 (2025): April-June 2025, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/305, DOI:https://doi.org/10.46121/pspc.53.2.31
25. Dr. Ohmini Krishnamurthy Rajendran (Author), SELF-SUPERVISED MULTIMODAL LEARNING FOR EARLY CANCER DETECTION ACROSS IMAGING AND GENOMICS, Vol. 52 No. 4 (2024): October-December 2024, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/325,DOI: https://doi.org/10.46121/pspc.52.4.14
26. Dr. Ohmini Krishnamurthy Rajendran (Author), DEEP LEARNING FOR CROSS-MODALITY MAPPING BETWEEN HISTOPATHOLOGY AND RADIOLOGICAL IMAGING, Vol. 53 No. 3 (2025): July-September 2025, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/326, DOI: https://doi.org/10.46121/pspc.53.3.21
27. Dr. Rajatha Maradi Hemanth Kumar (Author), MULTIMODAL FOUNDATION AI MODELS IN PRECISION ONCOLOGY: INTEGRATING RADIOMICS, PATHOMICS, MULTI-OMICS, AND CLINICAL INTELLIGENCE SYSTEMS, Vol. 52 No. 4 (2024): October–December 2024, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/343 , DOI: https://doi.org/10.46121/pspc.52.4.16
28. Dr. Ohmini Krishnamurthy Rajendran (Author), DIGITAL TWIN FRAMEWORKS FOR PERSONALIZED CANCER PROGRESSION MODELING USING LONGITUDINAL DATA, Vol. 53 No. 4 (2025): October-December 2025, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/327, DOI: https://doi.org/10.46121/pspc.53.4.33
29. Joshi, A. et al. (2023) ‘Multimodal Learning for Precision Oncology: Beyond Single-modality Analysis’, npj Precision Oncology, 7(1), p. 28.
30. Dr. Latha Kiran Krishna Rajendran (Author), Genomic Profiling: Utilizing Multi-Omics Data to Identify Potential Therapeutic Targets and Resistance Markers, Vol. 52 No. 4 (2024): October–December 2024, Power System Protection and Control, ISSN: 1674-3415, Article URL: https://pspac.info/index.php/dlbh/article/view/312 , DOI: https://doi.org/10.46121/pspc.52.4.13.